Axon Stock Slumps on Dilution Fears After $1 Billion Notes Plan
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Markets move fast. You should move faster. Be the first to know when deals break, stocks move, or biotech headlines hit. Sign up to get breaking news alerts the moment they happen.
Axon plans $1 billion of 0% convertible notes due 2031, plus a $150 million option.
Senators failed to reach 60 votes on the Clarity Act. All Democrats and four Republicans stopped debate on digital asset rules.
Veea and NovaGen signed a term sheet to combine and launch NovaGen Health Networks, a two-stage home health platform. The merger is not closed.
A new Google pilot pays publishers when content powers AI answers. Analysts say that cuts against Reddit’s push for more outbound traffic.
Waystar is reviewing options that may include a sale and a return to private ownership after its 2024 listing, Reuters reports.
Online lender Enova abandoned its $369 million Grasshopper deal, saying bank rules lack clear standards. It reaffirmed growth targets and plans more buybacks.